The Fund Grade · free · no account needed

What grade does HRCVX get?

Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.

Fundprints Fund Grade · as of 2026-09-01

Carillon Eagle Growth & Income Fund Class A

#108 of 440 graded active funds · growth · large segment peer group

The point · specialist footprint

HRCVX puts more of its book behind proven specialists than 82% of graded funds.

Bottom 20%

Bottom 40%

Middle

Top 40%

● Top 20%

beat the S&P in 22% of quarters+3.8 pts/qtr better · 43% beat rate

That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8 points per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.

2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice

The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.

Conviction exposure

35.3%

of the book in specialist-converged names

Late-stage weight

20.1%

of the book in Crowded or Fading names

Active share

87.2%

how far it strays from the index

The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.

Inside the book — top names by stage · as of 2026-09-09

Consensus

MSFT 5.1%JPM 4.3%ETN 3.3%+21 locked

Emerging

MCD 2.9%ABT 2.1%ICE 1.3%+1 locked

Crowded

T 3%MDT 2.4%NEE 1.8%+2 locked

Fading

AVGO 3.8%PG 3.1%TJX 2.8%+5 locked

see the names driving this grade, and how early each one is →

Watch this fund — free →X-ray what's inside →

We email you the day it crosses 50% crowded, and where you stand every month.

Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.

The read · what to do with it

Support leaving these positions

AVGO 3.8% of the fund · Fading

PG 3.1% of the fund · Fading

T 3% of the fund · Crowded

TJX 2.8% of the fund · Fading

MDT 2.4% of the fund · Crowded

Where it's genuinely early

MCD 2.9% of the fund · Emerging

ABT 2.1% of the fund · Emerging

ICE 1.3% of the fund · Emerging

Read from today's disclosed book. Evidence, not advice.

The evidence base updates this week.

The specialists — not the whales — are already positioned for what comes next. Stop finding out last.

Create your free account

No card required · open the feed in 30 seconds